A Rare Combination Of Endocrinopathies Associated With Camurati-Engelmann Disease

A case report of a patient with the rare autosomal dominant Camurati- Engelmann Disease (CED) associated with primary hypothyroidism, hypogonadotrophic hypogonadism and central diabetes insipidus is discussed. A thirty-five year old female with CED followed up for the past 27 years in our institution has pathognomonic musculo-skeletal features and multiple endocrinopathies. The clinical history, examination, ultrasound and laboratory investigations over the 27 years were evaluated. Conclusions: The clinical presentation of patients with CED is extremely variable. Although the endocrine glands are rarely affected, it is important to understand that endocrine dysfunction may manifest at different time in the progression of CED and respond well to replacement therapies. Taken together with the unpredictable genotype-phenotype correlations, regular endocrine, neurological and cardiac assessments as well as screening for other endocrinopathies are necessary. To the best of our knowledge, this is the first case of CED presented with a combination of the above three endocrinopathies reported in the literature. Please click  PDF  below to download the full paper...

[1]  P. Kantharidis,et al.  TGF-β Regulates miR-206 and miR-29 to Control Myogenic Differentiation through Regulation of HDAC4 , 2011, The Journal of Biological Chemistry.

[2]  M. Carlson,et al.  Skull base manifestations of Camurati-Engelmann disease. , 2010, Archives of otolaryngology--head & neck surgery.

[3]  J. Skucas,et al.  Camurati–Engelmann disease: imaging, clinical features and differential diagnosis , 2009, Skeletal Radiology.

[4]  J. Findlay,et al.  Transforming growth factor-beta: its role in ovarian follicle development. , 2008, Reproduction.

[5]  Yoon-Duck Kim,et al.  Bilateral visual loss in craniodiaphysial dysplasia. , 2006, American journal of ophthalmology.

[6]  Shaili Gupta,et al.  Camurati-Engelmann disease in conjunction with hypogonadism. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  A. Ramanan,et al.  Camurati-Engelmann disease--a case report and literature review. , 2005, Rheumatology.

[8]  S. Wientroub,et al.  Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment , 2005, Journal of Medical Genetics.

[9]  R. Derynck,et al.  Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. , 2003, The Journal of biological chemistry.

[10]  S. Ralston,et al.  Transforming Growth Factor-β1 Mutations in Camurati-Engelmann Disease Lead to Increased Signaling by Altering either Activation or Secretion of the Mutant Protein* , 2003, The Journal of Biological Chemistry.

[11]  P. Choudhury,et al.  Engelmann's disease with cardiomyopathy. , 2000, Indian pediatrics.

[12]  R. Gershoni-baruch,et al.  Localisation of the gene causing diaphyseal dysplasia Camurati-Engelmann to chromosome 19q13 , 2000, Journal of medical genetics.

[13]  A. Cupp,et al.  Expression and Action of Transforming Growth Factor Beta (TGFβ1, TGFβ2, and TGFβ3) during Embryonic Rat Testis Development , 1999 .

[14]  M. Sanders,et al.  Papilloedema, a complication of progressive diaphyseal dysplasia: a series of three case reports , 1998, The British journal of ophthalmology.

[15]  J. Massagué,et al.  Type beta transforming growth factor is an inhibitor of myogenic differentiation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Massagué,et al.  Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  N. Niikawa,et al.  Camurati-Engelmann disease type II: progressive diaphyseal dysplasia with striations of the bones. , 2002, American journal of medical genetics.

[18]  M. Feldmann,et al.  Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter. , 1989, The Journal of clinical investigation.